5-甲氧基-3,4-二氢-1H-喹啉-2-酮 | 30557-06-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 5-甲氧基-3,4-二氢-1H-喹啉-2-酮
• 英文名称: 5-methoxy-3,4-dihydroquinolin-2(1H)-one
• 英文别名: 5-methoxy-3,4-dihydro-1H-quinolin-2-one
• CAS: 30557-06-3
• 化学式: C₁₀H₁₁NO₂
• mdl: MFCD09955248
• 分子量: 177.203
• InChiKey: IAAVILGMVWQJDL-UHFFFAOYSA-N

物化性质

• 熔点：
  175-177 °C(Solv: methanol (67-56-1))
• 沸点：
  370.2±42.0 °C(Predicted)
• 密度：
  1.159±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933790090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  5-甲氧基-3,4-二氢-1H-喹啉-2-酮 在 sodium hydride 、 potassium carbonate 、 sodium iodide 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 11.0h， 生成 1-(3-(4-(3-氯苯基)-1-哌嗪基)丙基)-5-甲氧基-3,4-二氢-2-喹啉酮
  参考文献：
  名称：

  3,4-Dihydro-2(1H)-quinolinone as a Novel Antidepressant Drug:  Synthesis and Pharmacology of 1-[3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and Its Derivatives

  摘要：

  To develop a novel antidepressant drug with central nervous system-stimulating activity, me prepared a series of 1-[w-(4-substituted phenyl-1-piperazinyl)alkyl]-3,4-dihydro-2(1H)-quinlinone derivatives and examined their activities by their effects at 30 and 100 mg/kg po on the sleeping time of mice anesthetized with halothane and on the time required for recovery from coma induced in mice by cerebral concussion. We examined their binding affinities for a receptors by evaluating their ability to inhibit [H-3]-1,3-di(o-tolyl)guanidine ([H-3]DTG) binding to the rat whole brain membrane in comparison with three putative a receptor agonists: 1,3-di(o-tolyl)guanidine (DTG, 66), (+)-1,2,3,4,5,6-hexahydro-6,11-dimethylmethano-3-benzazecin-8-ol (SKF10,047, 67), and (+)-1,2,3,4,5,6-hexahydro-6, 11-dimethyl-3(3 -methyl-2-butenyl)-2,6-methano-3-benzazecin-8-ol (pentazocine, 68). Among the series of derivatives, 1-3-[4-(3-chlorophenyl)-1-piperazinyl]-3p linone hydrochloride (34b) and its mesylate (34c), at a dose of 30 mg/kg po, reduced the sleeping time and the time for recovery from coma and they inhibited [H-3]DTG binding for a receptors. The putative a receptor agonists reduced the sleeping time and the time for recovery from coma whereas two a receptor antagonists, alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl) piperazinebutanol hydrochloride (BMY14802, 69) and cis-9-[3-(3,5-dimethyl-1-piperazinyl)propyl]carbazole dihydrochloride (rimcazole, 70), were inactive in the two tests. Preadministration of the putative a receptor antagonists 69 (3 mg/kg po) and 70 (30 mg/kg po) completely antagonized the actions of 34b and the a receptor agonists in the test for recovery from coma. These results suggested that 34b and 34c are a receptor agonists. Furthermore, a single administration of 1 and 10 mg/kg po 34b and 34c showed antidepressant-like activity by reducing the immobility time in the forced-swimming test with mice, while a tricyclic antidepressant, 10,11-dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine hydrochloride (imipramine, 1) (10 and 30 mg/kg po), did not reduce the time after a single administration. 1 reduced the time after repeated administration of 30 mg/kg po once a day for 4 days. The structure-activity relationship of the series of compounds is also discussed.

  DOI：

  10.1021/jm980333v
• 作为产物：
  描述：

  2'-ethoxycarbonylethyl-3'-methoxy-2,2-dimethylpropionanilide 在 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 20.0h， 生成 5-甲氧基-3,4-二氢-1H-喹啉-2-酮
  参考文献：
  名称：

  5- {2- [4-（2-甲基-5-喹啉基）-1-哌嗪基]乙基} -2（1 H）-喹啉酮和3,4-二氢-2（1 H）-喹啉酮：双作用5-HT 1受体拮抗剂和5-羟色胺再摄取抑制剂。第三部分

  摘要：

  5- {2- [4-（2-甲基-5-喹啉基）-1-哌嗪基]乙基} -2（1 H）-喹啉酮和3,4-二氢-2（1 H）-喹啉酮已被鉴定为5-HT 1自体受体拮抗剂和hSerT效力的不同组合以及出色的大鼠PK谱。在已知在控制突触5-HT水平中起关键作用的靶标上具有一系列分布图的工具化合物的可用性将允许在一系列动物行为和疾病模型中探索不同的药理分布图。

  DOI：

  10.1016/j.bmcl.2010.09.085

文献信息

• [EN] CARBOSTYRIL COMPOUND<br/>[FR] DÉRIVÉ DE CARBOSTYRILE
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2006035954A1

  公开（公告）日：2006-04-06

  The present invention provides a carbostyril compound represented by General Formula (1) or a salt thereof, wherein A is a direct bond, a lower alkylene group, or a lower alkylidene group; X is an oxygen atom or a sulfur atom; R4 and R5 each represent a hydrogen atom; the bond between the 3 and 4 positions of the carbostyril skeleton is a single bond or a double bond; R1 is a hydrogen atom, etc; R2 is a hydrogen atom, etc; and R3 is a hydrogen atom, etc. The carbostyril compound or salt thereof of the present invention induces the production of TFF, and thus is usable for the treatment and/or prevention of disorders such as alimentary tract diseases, oral diseases, upper respiratory tract diseases, respiratory tract diseases, eye diseases, cancers, and wounds.

  本发明提供了一种由通式（1）表示的羧基吲哚化合物或其盐，其中A是直链键、较低的烷基烯基或较低的烷基亚烯基；X是氧原子或硫原子；R4和R5分别表示氢原子；羧基吲哚骨架的3和4位置之间的键是单键或双键；R1是氢原子，等等；R2是氢原子，等等；R3是氢原子，等等。本发明的羧基吲哚化合物或其盐诱导TFF的产生，因此可用于治疗和/或预防消化道疾病、口腔疾病、上呼吸道疾病、呼吸道疾病、眼部疾病、癌症和伤口等疾病。
• A study on the conversion of indanones into carbostyrils
  作者：Yasuhiro Torisawa、Takao Nishi、Jun-ichi Minamikawa

  DOI：10.1016/s0968-0896(03)00116-0

  日期：2003.5

  surveyed the utility of Beckmann rearrangement for the conversion of indanones into carbostyrils. Initial attempts at the conversion of 6-methoxy indanone oxime under classical conditions resulted in the formation of the two unusual products: 2-sulfonyloxyindanone and the dimeric product. This unusual rearrangement was also observed by the treatment of some metal triflates species. Further investigation

  我们已经调查了贝克曼重排用于将茚满酮转化为咔唑的效用。在经典条件下进行6-甲氧基茚满酮肟转化的初步尝试导致形成两种不同的产物：2-磺酰氧基茚满酮和二聚产物。通过处理一些金属三氟甲磺酸盐物种也观察到了这种异常的重排。进一步的研究导致了从甲磺酸肟（不是甲苯磺酸肟）开始的可靠条件的发展，其中在常规或非常规溶剂系统中使用了一些强路易斯酸催化剂（ZrCl（4））。通过简单的后处理和直接分离产品（65％的分离产率）突出了新协议的优势。
• Room Temperature Benzofused Lactam Synthesis Enabled by Cobalt(III)‐Catalyzed C( <i>sp</i> ² )−H Amidation
  作者：Xun Tian、Xin Li、Shengzu Duan、Ya Du、Tongqi Liu、Yongsheng Fang、Wen Chen、Hongbin Zhang、Minyan Li、Xiaodong Yang

  DOI：10.1002/adsc.202001254

  日期：2021.2.16

  Benzofused lactams, especially indolin‐2‐one and dihydroquinolin‐2‐one are popular structural motives in durgs and natural products. Herein, we developed a room temperature and robust synthesis of benzofused lactams through cobalt(III)‐catalyzed C(sp2)−H amidation. In this protocol, in‐situ formation of Cp*Co(III)(ligand) catalyst from Cp*Co(CO)I2 and ligand simplify the synthetic effort of cobalt

  苯并融合的内酰胺，尤其是吲哚-2-酮和二氢喹啉-2-酮是在草和天然产品中流行的结构动机。在本文中，我们开发了室温并且通过钴（III）催化的C（sp 2）-H酰胺化反应稳定合成苯并融合的内酰胺。在该协议中，由Cp * Co（CO）I 2和配体原位形成Cp * Co（III）（配体）催化剂可简化钴配合物的合成工作。简单且易于合成的1,4,2-二恶唑5-1在室温下进行分子内CH酰胺化反应，并以高达86％的收率提供了多种功能化的苯并融合内酰胺。还证明了反应的可扩展性。
• Rigid versus flexible anilines or anilides confirm the bicyclic ring as the hydrophobic portion for optimal σ₂ receptor binding and provide novel tools for the development of future σ₂ receptor PET radiotracers
  作者：Mauro Niso、Maria Laura Pati、Francesco Berardi、Carmen Abate

  DOI：10.1039/c6ra15783a

  日期：——

  Despite their uncertain identification, σ₂ receptors are promising targets for the development of diagnostics and therapeutics for tumor diseases.

  尽管它们的识别仍不确定，但σ2受体是肿瘤疾病诊断和治疗发展的有希望的靶点。
• 取代喹啉-2(1H)-酮化合物的制备方法和用途
  申请人：上海特化医药科技有限公司

  公开号：CN110467569B

  公开（公告）日：2022-10-21

  本发明属于药物化学和化学合成领域，具体涉及一类取代喹啉‑2(1H)‑酮化合物的制备方法。本发明提供了一种取代喹啉‑2(1H)‑酮化合物的制备方法，其将式I表示的化合物和氧化剂在溶剂中发生氧化反应，得到式II表示的化合物。该制备方法具有以下优点：方法简便、收率高、成本低、适于工业化生产，通式II表示的取代喹啉‑2(1H)‑酮为多种药物活性成分的重要中间体。